| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLLU1OS |
| Uniprot No | Q5K130 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-101aa |
| 氨基酸序列 | MNKLGHNELKECLKTATDSLQTVQPSISQTCTSYGPALGAPLPGRNEVALLTSLPPNYEISEGKPRAISAYVRAGKGNVTRRRKKTHLGNDDGKKEAQEKM |
| 分子量 | 38.06 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为假设性文献示例(实际文献需通过学术数据库验证)：
1. **文献名称**：*"Cloning and expression of recombinant human CLLU1OS protein in E. coli for diagnostic applications"*
**作者**：Smith J, et al.
**摘要**：报道了大肠杆菌表达系统中重组人CLLU1OS蛋白的克隆与纯化，证实其在慢性淋巴细胞白血病患者血清中作为潜在生物标志物的检测价值。
2. **文献名称**：*"Structural characterization and functional analysis of CLLU1OS protein in B-cell malignancies"*
**作者**：Lee H, et al.
**摘要**：通过X射线晶体学解析重组CLLU1OS蛋白结构，并揭示其与B细胞信号通路的相互作用，提示其在白血病病理中的调控机制。
3. **文献名称**：*"Development of a recombinant CLLU1OS-based ELISA kit for early leukemia screening"*
**作者**：Zhang R, et al.
**摘要**：基于重组CLLU1OS蛋白开发高灵敏度ELISA检测方法，临床样本验证显示其对早期CLL患者诊断特异性达92%。
4. **文献名称**：*"CLLU1OS recombinant protein induces apoptosis in leukemic cell lines"*
**作者**：Müller S, et al.
**摘要**：体外实验表明纯化的重组CLLU1OS蛋白可激活促凋亡蛋白Caspase-3.提示其作为靶向治疗分子的潜力。
---
注：实际研究中，CLLU1OS多与慢性淋巴细胞白血病(CLL)的预后相关，其重组蛋白研究可能集中于诊断试剂开发或机制探索。建议通过PubMed以“CLLU1OS recombinant protein”为关键词检索最新文献。
The recombinant human CLLU1OS protein originates from the CLLU1OS (Chronic Lymphocytic Leukemia Upregulated 1 Opposite Strand) gene, located on chromosome 12q22. Initially identified in chronic lymphocytic leukemia (CLL), this gene is transcriptionally active on the antisense strand of the CLLU1 locus. CLLU1OS encodes a protein implicated in cancer biology, particularly in CLL progression, where its overexpression correlates with poor prognosis and aggressive disease phenotypes. Studies suggest its involvement in modulating NF-κB signaling, a pathway critical for cell survival, inflammation, and drug resistance. The protein’s exact molecular functions remain under investigation, but it appears to interact with cellular components regulating apoptosis and proliferation.
Recombinant CLLU1OS protein is produced via heterologous expression systems (e.g., mammalian or bacterial cells) for functional and structural studies. Its production enables researchers to explore its role in leukemogenesis, screen therapeutic agents, and develop diagnostic biomarkers. Structural analyses reveal potential extracellular domains, hinting at its utility as a therapeutic target. While research is still in early stages, recombinant CLLU1OS serves as a vital tool for dissecting its pathological mechanisms and advancing CLL-targeted therapies. Its study also extends to other cancers, emphasizing its broader relevance in oncology.
×
